Acuitas Therapeutics Highlights In Vivo CAR T Cell Engineering and Ionizable Lipid Quality Attributes at the 2026 ASGCT Annual Meeting

Targeted extended circulation LNP incorporating DARPins achieved complete B cell depletion in nonhuman primates through highly specific in vivo CD8+ T cell engineering Robust study quantifies relationship between aldehydes as a key driver of mRNA-lipid adduct formation and mRNA-LNP product performance in vivo VANCOUVER, B.C. — Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP)... The post Acuitas Therapeutics Highlights In Vivo CAR T Cell Engineering and Ionizable Lipid Quality Attributes at the 2026 ASGCT Annual Meeting appeared first on Montreal Gazette .

Original source: Montreal Gazette